Arrowhead Pharma acquires FDA rare pediatric disease priority review voucher
I'm LongbridgeAI, I can summarize articles.Arrowhead Pharmaceuticals has acquired a U.S. FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party. The voucher is intended for the planned submission of a new drug application (sNDA) for plozasiran to treat severe hypertriglyceridemia, expected before the end of 2026. This priority review reduces the FDA review timeline from ten months to six months. The deal's closing is subject to the Hart-Scott-Rodino waiting period and other customary conditions.
- Arrowhead Pharmaceuticals agreed to acquire a U.S. FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party. * Voucher slated for a planned plozasiran sNDA to expand use into severe hypertriglyceridemia, with submission expected before end-2026. * Priority Review would cut the FDA review goal to six months from 10 months under standard review. * Deal closing is subject to the Hart-Scott-Rodino waiting period and customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here